E Keikkala1, P Vuorela, H Laivuori, J Romppanen, S Heinonen, U-H Stenman. 1. Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Biomedicum Helsinki, PB 700, 00029 Helsinki, Finland. Electronic address: elina.keikkala@hus.fi.
Abstract
INTRODUCTION: Recent studies indicate that treatment with low-dose aspirin may reduce the risk of preeclampsia. Thus, early prediction of preeclampsia is needed. Low serum concentrations of hyperglycosylated human chorionic gonadotrophin (hCG-h) are associated with early pregnancy loss. We therefore studied whether it may serve as an early marker of preeclampsia. METHODS: A nested case-control study included 158 women with subsequent preeclampsia, 41 with gestational hypertension, 81 normotensive women giving birth to small-for-gestational-age (SGA) infants and 427 controls participating in first trimester screening for Down's syndrome between 8 and 13 weeks of gestation. Gestational-age-adjusted multiples of medians (MoMs) were calculated for serum concentrations of hCG-h, the free beta subunit of hCG (hCGβ) and pregnancy-associated plasma placental protein A (PAPP-A) and the proportion of hCG-h to hCG (%hCG-h). Clinical risk factors including mean arterial pressure (MAP) and parity were also included in the risk calculation. RESULTS: In women with subsequent preeclampsia %hCG-h was lower than in controls (median MoM 0.92, P < 0.001), especially in 29 cases with early-onset preeclampsia (0.86, P < 0.001), in which PAPP-A also was reduced (0.95, P = 0.001). At 90% specificity for prediction of early-onset preeclampsia, sensitivity was 56% (95% confidence interval, 52-61%) for %hCG-h, 33% (28-37%) for PAPP-A, and 69% (51-83%) for the combination of these with first trimester MAP and parity. The area under the receiver-operating characteristic (ROC) curve for the combination of all these was 0.863 (0.791-0.935). CONCLUSIONS: hCG-h is a promising first trimester marker for early-onset preeclampsia. Addition of PAPP-A and maternal risk factors may improve the results.
INTRODUCTION: Recent studies indicate that treatment with low-dose aspirin may reduce the risk of preeclampsia. Thus, early prediction of preeclampsia is needed. Low serum concentrations of hyperglycosylated human chorionic gonadotrophin (hCG-h) are associated with early pregnancy loss. We therefore studied whether it may serve as an early marker of preeclampsia. METHODS: A nested case-control study included 158 women with subsequent preeclampsia, 41 with gestational hypertension, 81 normotensive women giving birth to small-for-gestational-age (SGA) infants and 427 controls participating in first trimester screening for Down's syndrome between 8 and 13 weeks of gestation. Gestational-age-adjusted multiples of medians (MoMs) were calculated for serum concentrations of hCG-h, the free beta subunit of hCG (hCGβ) and pregnancy-associated plasma placental protein A (PAPP-A) and the proportion of hCG-h to hCG (%hCG-h). Clinical risk factors including mean arterial pressure (MAP) and parity were also included in the risk calculation. RESULTS: In women with subsequent preeclampsia %hCG-h was lower than in controls (median MoM 0.92, P < 0.001), especially in 29 cases with early-onset preeclampsia (0.86, P < 0.001), in which PAPP-A also was reduced (0.95, P = 0.001). At 90% specificity for prediction of early-onset preeclampsia, sensitivity was 56% (95% confidence interval, 52-61%) for %hCG-h, 33% (28-37%) for PAPP-A, and 69% (51-83%) for the combination of these with first trimester MAP and parity. The area under the receiver-operating characteristic (ROC) curve for the combination of all these was 0.863 (0.791-0.935). CONCLUSIONS:hCG-h is a promising first trimester marker for early-onset preeclampsia. Addition of PAPP-A and maternal risk factors may improve the results.
Keywords:
Hyperglycosylated human chorionic gonadotrophin; Preeclampsia; Pregnancy-associated plasma protein A; Sensitivity and specificity; Small-for-gestational-age
Authors: Anna Yliniemi; Kaarin Makikallio; Teemu Korpimaki; Heikki Kouru; Jaana Marttala; Markku Ryynanen Journal: Clin Med Insights Reprod Health Date: 2015-06-11
Authors: Chinedu Nwabuobi; Sefa Arlier; Frederick Schatz; Ozlem Guzeloglu-Kayisli; Charles Joseph Lockwood; Umit Ali Kayisli Journal: Int J Mol Sci Date: 2017-09-22 Impact factor: 5.923
Authors: Mirjana Barjaktarovic; Tim I M Korevaar; Vincent W V Jaddoe; Yolanda B de Rijke; Theo J Visser; Robin P Peeters; Eric A P Steegers Journal: Eur J Epidemiol Date: 2016-10-05 Impact factor: 8.082
Authors: Katja Murtoniemi; Pia M Villa; Jaakko Matomäki; Elina Keikkala; Piia Vuorela; Esa Hämäläinen; Eero Kajantie; Anu-Katriina Pesonen; Katri Räikkönen; Pekka Taipale; Ulf-Håkan Stenman; Hannele Laivuori Journal: BMC Pregnancy Childbirth Date: 2018-07-03 Impact factor: 3.007